Topka S, Vijai J, Walsh MF, Jacobs L, Maria A, Villano D, Gaddam P, Wu G, McGee RB, Quinn E et al..
2015.
Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.. PLoS Genet. 11(6):e1005262.
Bergstrom KSB, Morampudi V, Chan JM, Bhinder G, Lau J, Yang H, Ma C, Huang T, Ryz N, Sham HPan et al..
2015.
Goblet Cell Derived RELM-β Recruits CD4+ T Cells during Infectious Colitis to Promote Protective Intestinal Epithelial Cell Proliferation.. PLoS Pathog. 11(8):e1005108.
Bergstrom KSB, Morampudi V, Chan JM, Bhinder G, Lau J, Yang H, Ma C, Huang T, Ryz N, Sham HPan et al..
2015.
Goblet Cell Derived RELM-β Recruits CD4+ T Cells during Infectious Colitis to Promote Protective Intestinal Epithelial Cell Proliferation.. PLoS Pathog. 11(8):e1005108.
Chen L, He Z, Slinger E, Bongers G, T Lapenda L, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N et al..
2015.
IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology.. Mucosal Immunol. 8(2):390-402.
Chen L, He Z, Slinger E, Bongers G, T Lapenda L, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N et al..
2015.
IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology.. Mucosal Immunol. 8(2):390-402.
Chen L, He Z, Slinger E, Bongers G, T Lapenda L, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N et al..
2015.
IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology.. Mucosal Immunol. 8(2):390-402.
Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J, Withers DR, Hugues S, Farrar MA, Reith W et al..
2015.
Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells.. Science. 348(6238):1031-5.
Tang J, Iliev ID, Brown J, Underhill DM, Funari VA.
2015.
Mycobiome: Approaches to analysis of intestinal fungi.. J Immunol Methods. 421:112-21.
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen W-P, Mo A, Tucker C, Bhattacharya A et al..
2015.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.. Cancer Prev Res (Phila). 8(3):222-30.
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen W-P, Mo A, Tucker C, Bhattacharya A et al..
2015.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.. Cancer Prev Res (Phila). 8(3):222-30.
Hirten R, Longman RS, Bosworth BP, Steinlauf A, Scherl E.
2015.
Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.. Am J Gastroenterol. 110(12):1737-8.